Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Eiropas Savienība - latviešu - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Zomarist Eiropas Savienība - latviešu - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Mounjaro Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mounjaro

eli lilly nederland b.v. - tirzepatide - cukura diabēts, 2. tips - cukura diabēts - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 un 5.

Skudexa 75 mg/25 mg granulas iekšķīgi lietojama šķīduma pagatavošanai paciņā Latvija - latviešu - Zāļu valsts aģentūra

skudexa 75 mg/25 mg granulas iekšķīgi lietojama šķīduma pagatavošanai paciņā

menarini international operations luxembourg s.a., luxembourg - tramadoli hydrochloridum, dexketoprofenum - granulas iekšķīgi lietojama šķīduma pagatavošanai paciņā - 75 mg/25 mg

Glidipion (previously Pioglitazone Actavis Group) Eiropas Savienība - latviešu - EMA (European Medicines Agency)

glidipion (previously pioglitazone actavis group)

actavis group ptc ehf    - pioglitazona hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone ir arī norādīts kombinācija ar insulīnu, 2. tipa cukura diabēts pieaugušiem pacientiem ar nepietiekamu glycaemic kontroli uz insulīnu, kam metformīns ir nevietā, jo ir kontrindikācijas vai neiecietību. pēc tam, kad sākta terapija ar pioglitazone, pacientiem būtu jāpārskata pēc 3 līdz 6 mēnešiem, lai novērtētu atbilstību ārstēšanas e. samazinājums hba1c). pacientiem, kas nespēj izrādīt pienācīgu atbildi, pioglitazone būtu jāpārtrauc. Ņemot vērā potenciālos riskus, ar ilgstošu terapiju, prescribers jāapstiprina turpmāk kārtējās atsauksmes, ka labā pioglitazone ir vēsture.

Oltar 2 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

oltar 2 mg tabletes

berlin-chemie ag, germany - glimepirīds - tablete - 2 mg

Meglimid 2 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

meglimid 2 mg tabletes

krka, d.d., novo mesto, slovenia - glimepirīds - tablete - 2 mg

Meglimid 3 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

meglimid 3 mg tabletes

krka, d.d., novo mesto, slovenia - glimepirīds - tablete - 3 mg

Glimepiride Accord 4 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

glimepiride accord 4 mg tabletes

accord healthcare b.v., netherlands - glimepirīds - tablete - 4 mg

Glimepiride Accord 1 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

glimepiride accord 1 mg tabletes

accord healthcare b.v., netherlands - glimepirīds - tablete - 1 mg